Compare · ALNY vs NVS
ALNY vs NVS
Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALNY and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 7.2x ALNY ($39.01B).
- Over the past year, ALNY is down 1.6% and NVS is up 26.0% - NVS leads by 27.6 points.
- ALNY has hit the wire 18 times in the past 4 weeks while NVS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Alnylam Pharmaceuticals Inc.
- Novartis AG
- Price
- $300.79+2.98%
- $148.72+1.52%
- Market cap
- $39.01B
- $279.39B
- 1M return
- +1.47%
- +1.86%
- 1Y return
- -1.64%
- +26.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 25
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ALNY
- Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
- Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)
- SEC Form 4 filed by Director Cravatt Benjamin
- SEC Form 3 filed by new insider Cravatt Benjamin
- SEC Form 144 filed by Alnylam Pharmaceuticals Inc.
- Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
- Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)
- Director Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)
- Director Reitan Colleen F was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG